Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tumor Ablation Clear all
Terminated No phase listed Observational

The STAR™ Tumor Ablation Registry

NCT02419703
View directory record Official record
Conditions
Metastatic Lesions in Vertebral Bodies
Interventions
STAR™ Tumor Ablation System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
22 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Concord, California • Escondido, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

NCT00004635
View directory record Official record
Conditions
Prostate Cancer
Interventions
Thalidomide, leuprolide acetate, goserelin, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
9
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 30, 2026, 5:52 AM EDT
Active, not recruiting Early Phase 1 Interventional

Itraconazole to Prevent Recurrent Barrett's Esophagus

NCT05609253
View directory record Official record
Conditions
Barrett Oesophagitis With Dysplasia
Interventions
Itraconazole in capsule form, Itraconazole in solution form
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Not listed Not applicable Interventional

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

NCT01972867
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife Procedure
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

NCT00081159
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
4
States / cities
Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Sep 30, 2026, 5:52 AM EDT
Not listed No phase listed Observational

Photodynamic Therapy (PDT) Cholangiocarcinoma Registry

NCT01524146
View directory record Official record
Conditions
Unresectable Cholangiocarcinoma, Biliary Obstruction, Stent Obstruction, Biliary Stricture
Interventions
Photodynamic Therapy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

NCT00116779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 30, 2026, 5:52 AM EDT
Not listed Phase 1 Interventional

Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

NCT00103155
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
conventional surgery, radiofrequency ablation
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Sep 30, 2026, 5:52 AM EDT
Active, not recruiting Not applicable Interventional

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

NCT01494324
View directory record Official record
Conditions
Liver Cancer
Interventions
CT guided percutaneous ablation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 30, 2026, 5:52 AM EDT
Active, not recruiting Not applicable Interventional

Excision Followed by Radiofrequency Ablation for Breast Cancer

NCT01153035
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiofrequency Ablation
Device
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting No phase listed Observational

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

NCT06937996
View directory record Official record
Conditions
Pancreatic Cancer Non-resectable
Interventions
NanoKnife
Device
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

NCT04699773
View directory record Official record
Conditions
Glioma, Glioblastoma, Brain Tumor
Interventions
LITT, Hypofractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional

Computer Guided Microwave Liver Ablation

NCT07226869
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Computer-Assisted Microwave Liver Ablation
Device
Lead sponsor
NE Scientific INC
Industry
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Active, not recruiting Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Phase 1 Interventional

Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain

NCT07117032
View directory record Official record
Conditions
Pancreatic Cancer, Retroperitoneal Pain Syndrome
Interventions
Simulation-free workflow, Celiac plexus SBRT
Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Phase 1 Interventional

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

NCT06205849
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
IRE + intratumoral mitazalimab (CD40 antibody) injection, NanoKnife
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Not applicable Interventional

Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00388115
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, neoadjuvant therapy, radiofrequency ablation
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Phase 2 Interventional

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

NCT06558214
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, Optune GIO®, NeuroBlate®
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation

NCT00571987
View directory record Official record
Conditions
Cancer of the Breast
Interventions
AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 30, 2026, 5:52 AM EDT
Not listed No phase listed Observational

Comparison of a Novel Ultrasound System Versus Standard Imaging Modalities

NCT05748106
View directory record Official record
Conditions
Image-Guided Biopsies and/or Ablations
Interventions
Ultrasound-based imaging
Device
Lead sponsor
MAUI Imaging, Inc.
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting No phase listed Observational

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

NCT05363657
View directory record Official record
Conditions
Kidney Cancer
Interventions
Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT), Active Surveillance (AS)
Procedure · Diagnostic Test
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Sep 30, 2026, 5:52 AM EDT